中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 药物靶标结构与功能中心
Crystal structure-based comparison of two NAMPT inhibitors

文献类型：期刊论文

作者Zhang, Sai-long3; Xu, Tian-ying3; Yang, Zhen-lin1; Han, Shuo1; Zhao, Qiang1; Miao, Chao-yu2,3
刊名ACTA PHARMACOLOGICA SINICA
出版日期2018-02
卷号39期号:2页码:294-301
关键词nicotinamide phosphoribosyltransferase (NAMPT) FK866 MS0 anticancer drugs antiproliferation crystal structure binding mode
ISSN号1671-4083
DOI10.1038/aps.2017.80
文献子类Article
英文摘要Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) is a novel strategy for cancer therapy, but only two inhibitors of NAMPT (FK866 and CHS828) have progressed into clinical trials. This study seeks to compare a novel potent NAMPT inhibitor, MS0, with a classical inhibitor FK866 in their biological activity and molecular binding mode, thereby contributing to future chemical optimization and a further understanding of the action mode of NAMPT inhibitors. The IC50 values of MS0 and FK866 in inhibition of recombinant human NAMPT activity were 9.08 +/- 0.90 and 1.60 +/- 0.32 nmol/L, respectively. Consistently, FK866 exerted better antiproliferation in 6 human cancer cell lines (HepG2, A2780, 95-D, A549, U2OS and U266) than MS0 with IC50 values nearly 12-fold to 225-fold lower than those of MS0. Co-crystal structures of wild-type human NAMPT complexed with MS0 or FK866 were elucidated, which revealed that MS0 did not interact with Ser241. The hydrogen bond mediated by crystallographic water between MS0 and His191 or Val350 of NAMPT did not exist in FK866. Instead, FK866 exhibited hydrophobic interactions with Arg349. Based on the activity assays and crystal structure analyses, we elaborate the reason why the antiproliferation activity of MS0 was not as good as that of FK866, which would contributes to the current understanding of the mode of action of NAMPT inhibitors and will also contribute to further development of anticancer drugs in the future.
WOS关键词NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE NAMPT ; COLONY-ENHANCING FACTOR ; IN-VITRO ; PHASE-I ; CHS 828 ; IDENTIFICATION ; CELLS ; BIOSYNTHESIS ; RESISTANCE ; FK866
资助项目National Natural Science Foundation of China[81130061] ; National Natural Science Foundation of China[81373414] ; Shanghai Municipal Science and Technology Project[16431901400] ; Shanghai Municipal Science and Technology Project[16140904500]
WOS研究方向Chemistry ; Pharmacology & Pharmacy
语种英语
CSCD记录号CSCD:6163695
WOS记录号WOS:000423868000015
出版者ACTA PHARMACOLOGICA SINICA
源URL[http://119.78.100.183/handle/2S10ELR8/279937]  
专题药物靶标结构与功能中心
通讯作者Zhao, Qiang; Miao, Chao-yu
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China;
2.Beijing Inst Brain Disorders, Ctr Stroke, Beijing 100069, Peoples R China
3.Second Mil Med Univ, Dept Pharmacol, Shanghai 200433, Peoples R China;
推荐引用方式
GB/T 7714		 Zhang, Sai-long,Xu, Tian-ying,Yang, Zhen-lin,et al. Crystal structure-based comparison of two NAMPT inhibitors[J]. ACTA PHARMACOLOGICA SINICA,2018,39(2):294-301.
APA Zhang, Sai-long,Xu, Tian-ying,Yang, Zhen-lin,Han, Shuo,Zhao, Qiang,&Miao, Chao-yu.(2018).Crystal structure-based comparison of two NAMPT inhibitors.ACTA PHARMACOLOGICA SINICA,39(2),294-301.
MLA Zhang, Sai-long,et al."Crystal structure-based comparison of two NAMPT inhibitors".ACTA PHARMACOLOGICA SINICA 39.2(2018):294-301.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。